Case report highlights bisphosphonates may complicate hyperparathyroidism diagnosis in kidney transplant recipients, suggesting careful evaluation of bone disorders first.
Present case emphasizes the importance of controlling CKD-mineral and bone disorders prior to initiating bone targeting drugs, as also has been recommended by recent consensus manuscripts. In an era in which bone turnover markers gain importance in guiding PTH suppressive and osteoporosis therapy, antiresorptive agents may complicate the diagnosis of hyperparathyroidism by masking the bone phenotype.
No takes yet. Share an insight, caveat, or question.
Engelen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: